WeLeader Biomedical Co., Ltd. (TPEX:7713)

Market Cap	3.23B -3.3%
Revenue (ttm)	1.06B +9.0%
Net Income	191.02M +14.3%
EPS	4.33 +8.2%
Shares Out	45.48M
PE Ratio	16.40
Forward PE	n/a
Dividend	3.37 (4.74%)
Ex-Dividend Date	Jun 3, 2025

Volume	12,400
Average Volume	12,934
Open	70.00
Previous Close	70.90
Day's Range	70.00 - 71.00
52-Week Range	54.20 - 83.00
Beta	0.01
RSI	46.96
Earnings Date	Mar 13, 2026

About WeLeader Biomedical

WeLeader Biomedical Co., Ltd. operates as an agent and distributor of in vitro diagnostic products. It offers a range of medical testing systems, such as serum biochemistry integration platform, clinical care, and medical information integration system. The company also provides blood gas electrolyte analyzers, urine analyzers, integrated fully automatic biochemical analyzers, fully automatic electronic luminescence immunoassay products, fully automatic modular biochemical immune assay products, TTA automated pre-processing products, POCT centr...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1992
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7713

Financial Performance

In 2024, WeLeader Biomedical's revenue was 991.13 million, an increase of 5.36% compared to the previous year's 940.70 million. Earnings were 170.21 million, an increase of 11.77%.